HOME >> BIOLOGY >> NEWS
16th EORTC NCI AACR Symposium

The revolution in understanding the molecular basis of cancer has lead to the discovery and development of numerous innovative agents 'designer' diagnostics, new prognostic tests, 'smart' drugs and other entirely novel ways of tackling cancer.

To bring these new developments to patients as quickly and efficiently as possible requires international collaboration, early and optimal exchange of information, good quality translational research, efficient drug development and large prospective clinical trials.

Three of the world's leading cancer organisations:

  • The European Organisation for Research and Treatment of Cancer;
  • The USA's National Cancer Institute;
  • The American Association for Cancer Research;

    will join forces in Geneva from 28 September to 1 October to provide a platform for presentation of the latest findings in drug research and development to around 2,000 international experts in the field.

    All data at the four-day meeting are being presented for the first time.

    We welcome the media to the symposium. Every session is open to journalists and registration is free to bona fide media presenting official press credentials, or a letter from the editor of the journal they represent stating that they are being commissioned to write a report for publication.

    A media centre with computing, fax, photocopying and free international phone and internet connections will be available.

    NB: the official language of the symposium is English and all press materials will be in English.

    To register: contact Margaret Willson for a registration form or download one from the conference website.


    '"/>



    • Contact: Margaret Willson
    m.willson@mwcommunications.org.uk
    44-015-367-72181
    European Organisation for Research and Treatment of Cancer
    19-Jul-2004


    Page: 1

    Related biology news :

    1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
    2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    3. Final Alert: 16th EORTC NCI AACR Symposium
    4. Clock cells, tumor suicide, tailored therapies among subjects of AACR-NCI-EORTC Conference
    5. 14th EORTC NCI AACR Symposium
    6. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
    7. Health of worlds sea lions the focus of Wakefield Symposium
    8. Chemical signals health of brain cells Symposium
    9. Symposium to tackle questions of genetic engineering and biodiversity
    10. Fostering Diversity in the Sciences Symposium
    11. Annual Chemical Biology Symposium at Yale May 14, 2004

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    		TAG: EORTC NCI AACR Symposium

    (Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
    (Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
    (Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
    Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
    (Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
    (Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
    (Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
    (Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
    Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
    Cached News: